Wernze H, Spech H J, Müller G
Klin Wochenschr. 1978 Apr 15;56(8):389-97. doi: 10.1007/BF01477293.
Plasma renin activity (PRA), plasma renin concentration (PRC), angiotensinogen, angiotensin II (AT II) and plasma aldosterone were determined by radioimmunoassay in 77 patients with cirrhosis of the liver [group I: with ascites, untreated (n=23); group II: patients with ascites during treatment (n=32); group III: after removal of fluids, but under further spironolactone therapy (n=10); group IV: untreated subjects without ascites (n=12)]. With the exception of decreased angiotensinogen values in all groups ranging between 39% (group IV) and 73% (group III) no significant changes of the other parameters of the RAAS were found in untreated patients. A highly significant increase of PRA, PRC, AT II and plasma aldosterone was observed in treated cirrhotics with (group II) or without (group III) ascites. In the total series of patients AT II was closely related to PRA, PRC and aldosterone emphasizing aldosterone secretion. Plasma sodium was inversely correlated to PRA, PRC, AT II and aldosterone, but no relationship was detected between these parameters of the RAAS and plasma potassium. Our results indicate that hyperaldosteronism in cirrhosis appears unlikely to be the major determinant of avid renal sodium retention and ascites formation. An increased activity of the RAAS is most often initiated by therapeutic factors and/or markedly altered electrolyte metabolism. Therefore, basal conditions of the patients to be studied must be well defined to exclude any artificially induced stimulation of the RAAS.
采用放射免疫分析法对77例肝硬化患者进行了血浆肾素活性(PRA)、血浆肾素浓度(PRC)、血管紧张素原、血管紧张素II(AT II)及血浆醛固酮的测定[第一组:有腹水,未治疗(n = 23);第二组:治疗期间有腹水的患者(n = 32);第三组:抽液后,但继续接受螺内酯治疗(n = 10);第四组:无腹水的未治疗受试者(n = 12)]。除所有组的血管紧张素原值均降低外,降低幅度在39%(第四组)至73%(第三组)之间,未治疗患者的肾素 - 血管紧张素 - 醛固酮系统(RAAS)其他参数未见显著变化。在有(第二组)或无(第三组)腹水的经治疗的肝硬化患者中,观察到PRA、PRC、AT II及血浆醛固酮显著升高。在全部患者系列中,AT II与PRA、PRC及醛固酮密切相关,强调醛固酮分泌。血浆钠与PRA、PRC、AT II及醛固酮呈负相关,但未检测到RAAS的这些参数与血浆钾之间存在关联。我们的结果表明,肝硬化中的高醛固酮血症似乎不太可能是肾钠潴留和腹水形成的主要决定因素。RAAS活性增加最常由治疗因素和/或明显改变的电解质代谢引发。因此,必须明确界定待研究患者的基础状况,以排除任何人为诱导的RAAS刺激。